Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 10, 2017

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2026

Conditions
Plasmacytoma
Interventions
DRUG

Lenalidomide

Experimental Arm

DRUG

Dexamethasone

Experimental Arm

OTHER

No further treatment

Comparator Arm

Trial Locations (13)

Unknown

Royal United Hospital, Bath

Blackpool Victoria Hospital, Blackpool

University Hospital Wales, Cardiff

Velindre Cancer Centre, Cardiff

Beatson West of Scotland Cancer Centre, Glasgow

St James University Hospital, Leeds

University College London Hospital, London

The Christie Hospital, Manchester

Freeman Hospital, Newcastle

Mount Vernon Cancer Centre, Northwood

Royal Preston Hospital, Preston

Salisbury District Hospital, Salisbury

Southampton General Hospital, Southampton

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Cancer Research UK

OTHER

collaborator

Celgene

INDUSTRY

lead

University College, London

OTHER